{"nctId":"NCT00440297","briefTitle":"Hepatitis B Vaccine Predialysis/Dialysis Study (V232-060)","startDateStruct":{"date":"2006-12"},"conditions":["Hepatitis B Virus Infection"],"count":277,"armGroups":[{"label":"Modified process hepatitis B vaccine","type":"EXPERIMENTAL","interventionNames":["Biological: Comparator: modified process hepatitis B vaccine"]},{"label":"ENGERIX-B™2","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Comparator: ENGERIX-B™"]}],"interventions":[{"name":"Comparator: modified process hepatitis B vaccine","otherNames":[]},{"name":"Comparator: ENGERIX-B™","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male and female subjects at least 18 years of age\n* Laboratory confirmed negative serology result to HbsAg (hepatitis b virus), anti-HBs (antibody to hepatitis B surface antigen), and anti HBc (antibody to hepatitis B core antigen) within 6 weeks of the initial dose of study vaccine\n* Patient on renal dialysis or a pre-dialysis patient with a creatinine clearance of \\<=30 ml/min\n\nExclusion Criteria:\n\n* Previous hepatitis B infection, vaccination with any hepatitis B vaccine\n* Recent febrile illness; hypersensitivity to any component of licensed hepatitis B vaccines\n* Recent administration of immune globulin, licensed inactivated vaccine within 14 days or licensed live vaccine within 30 days prior to receipt of first study vaccine\n* Receipt of investigational drugs or investigational vaccines within 3 months prior\n* Impairment of immunologic function\n* Recent use of systemic immunomodulatory medications\n* Pregnant women, nursing mothers or women planning to become pregnant","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Number of Seroprotected Participants to the Modified Process Hepatitis B Vaccine and ENGERIX-B™ (Currently Licensed Vaccine) at Month 7","description":"The number of participants as measured by the\n\nseroprotection rate (anti-hepatitis B surface antibodies greater than or equal to 10 mIU/mL). Anti-HBs (Antibodies against hepatitis B surface antigen) titers were measured from blood samples taken at Day 1 (prior to the first dose) and at Month 7 (1 month after the third dose).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"64","spread":null}]}]}]},{"type":"PRIMARY","title":"The Number of Seroprotected Participants to the Modified Process Hepatitis B Vaccine and ENGERIX-B™ (Currently Licensed Vaccine) at Month 9","description":"The number of participants as measured by the\n\nseroprotection rate (anti-hepatitis B surface antibodies greater than or equal to 10 mIU/mL). Anti-HBs (Antibodies against hepatitis B surface antigen) titers were measured from blood samples taken at Day 1 (prior to the first dose) and at Month 9 (1 month after the fourth dose).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66","spread":null},{"groupId":"OG001","value":"72","spread":null}]}]}]},{"type":"PRIMARY","title":"The Total Number of Participants With One or More Injection-Site Adverse Experiences","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"48","spread":null}]}]}]},{"type":"PRIMARY","title":"The Total Number of Participants With a Maximum Temperature >= 100.0F / 37.8C","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"PRIMARY","title":"The Total Number of Participants With Serious Vaccine-Related Clinical Adverse Experiences","description":"Participants with adverse experiences considered possibly, probably, or definitely related to study vaccines and considered serious (death, persistent disability, life threatening, hospitalization, birth defects, cancer, or overdose).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11},"commonTop":["Injection site Pain","Injection site Erythema","Injection site Swelling","Headache","Diarrhea"]}}}